Teva Pharmaceuticals has launched a voluntary recall into two drugs used to treat high blood pressure as yet more medications face concerns over a possible cancer risk.

In a statement from Teva posted by the Food and Drug Administration, the recall affects all lots of combination tablets featuring the drugs amlodipine and valsartan and another combo drug featuring amlodipine, valsartan, and hydrochlorothiazide.

The drugs could contain an impurity called N-nitroso-diethylamine (NDEA), which has been classified as a possible human carcinogen, the FDA said.

Patients taking either drugs should contact their doctor or pharmacist for advice or alternative treatments. Stopping the drugs immediately with no comparable alternative could pose a greater risk to patients' health, said Teva.

More:Doctors: Blood pressure drug substitutes are available for patients affected by recalls

More:FDA chief: Blood pressure medicine recalls reflect increased scrutiny on drug safety

More:Want more news like this? Subscribe to get the Daily Briefing in your inbox.

Customers and patients with questions can contact Teva by phone at 888-838-2872, or email at druginfo@tevapharm.com.

In August, the FDA announced an expanded recall of valsartan because products may contain the impurity. Last month, two more recalls were announced: one for the drug irbesartan and a second recall for losartan potassium hydrochlorothiazide tablets.

During an interview in November with USA TODAY, FDA commissioner Scott Gottlieb said the blood pressure drug recalls reflect an increased focus on drug quality to ensure no impurities are present.

Follow Brett Molina on Twitter: @brettmolina23.